admin – Page 5679 – Get News Story

Achondroplasia Market is Expected to Show a Significant Growth During the Forecast Period | Pfizer, Sanofi, ProLynx, PhaseBio, Ascendis, BioMarin

“Achondroplasia Market”

According to DelveInsight, the dynamics of the Achondroplasia market are expected to shift in the coming years due to the introduction of new emerging drugs, government backing for clinical development, and a rising number of Achondroplasia cases across the 7MM.

Several major pharma and biotech giants are persistently working towards the development of novel treatment therapies that can address the defects caused by FGFR3 gene mutation. There are several promising drugs in the pipeline, including TransCon CNP (Ascendis Pharma), Infigratinib (BridgeBio), Recifercept (Pfizer), and RBM-007 (Ribomic Inc), among others.

DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Achondroplasia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Achondroplasia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Achondroplasia Overview

Achondroplasia is a genetic disorder characterized by an unusually large head (macrocephaly), short upper arms (rhizomelic dwarfism), and short stature (adult height of approximately 4 feet). FGFR genetic alterations can cause more than 99% of Achondroplasia cases. In a small proportion of infants, symptoms like excessive accumulation of fluid around the brain (hydrocephalus) and low muscle tone (hypotonia) may happen as typical of achondroplasia. Acquisition of developmental motor milestones may also be delayed.

Achondroplasia results in short-limb skeletal dysplasia, occurring in approximately 1 in 20,000-30,000 live births. This genetic disorder is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, which occurs due to a spontaneous genetic mutation in approximately 80 percent of patients, and in the remaining 20 percent, it is inherited from a parent.

The current treatment landscape includes medications such as growth hormone therapy, surgery, and supportive therapy for achondroplasia. The first drug to be approved for treating achondroplasia is VOXZOGO (Vosoritide) by BioMarin Pharmaceuticals. The European Commission granted marketing authorization to VOXZOGO as a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height, in August 2021. In November 2021, US FDA approved VOXZOGO, under accelerated approval pathway, and Rare Pediatric Disease Priority Review Voucher, fastening the approval timeline. Marketing authorization reviews are in process in Japan, Brazil, and Australia, with potential approvals in these countries in 2022.

Achondroplasia Market Key Facts

The diagnosed prevalence of achondroplasia has been increasing in the US due to improved understanding among healthcare professionals, advances in diagnosis, besides an increasing population.

Advances in genetic testing, such as chorionic villus sampling, new-generation sequencing, and amniocentesis, allow for the prenatal diagnosis of achondroplasia.

Management of achondroplasia is symptomatic and requires a multidisciplinary approach involving pharmacological and nonpharmacological interventions. The current treatment landscape has only one approved therapy in the US and Europe, VOXZOGO (vosoritide), while in Japan, growth hormone has also been authorized for the management of achondroplasia; however, its long-term benefits are controversial.

Other therapies like statins, anti-infectives, antihistamines, CNP analogs, etc, are also used to manage symptoms and aid surgical procedures of achondroplasia. Further, surgical therapies like adenotonsillectomy, suboccipital decompression, tracheostomy, laminectomy, and physical therapy play a vital role in managing several complications of achondroplasia.

One of the major concerns in understanding the achondroplasia market is the paucity of evidence to validate interventions used in the daily management of achondroplasia.

There is a lack of curative therapy; however, the presence of clinical and diagnostic guidelines, recommendations, and consensus statements have enabled informed treatment and management, the American Academy of Pediatric’s Health Supervision for Children with Achondroplasia, International Consensus Statement on the Diagnosis, Multidisciplinary Management, and Lifelong Care of Individuals with Achondroplasia, and Japanese Society for Pediatric Endocrinology’s Clinical Practice Guidelines for Achondroplasia are few among them. However, the detailed basis for recommendations and the existing uncertainties are yet to be explored.

Achondroplasia is associated with poor quality of life, substantial economic burdens, negative stereotypes, and social challenges.

In 2022, the US had the largest market size of achondroplasia among the 7MM, accounting for approximately USD 111.85 million, expected to increase further by 2032.

The approved drug is VOXZOGO (vosoritide), a C-type natriuretic peptide (CNP) analog, which acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth. The drug is indicated to increase linear growth in children with achondroplasia having open epiphyses.

Although much has been learned about the disorder, limited pharmacological therapies are available, and surgeries have the risk of morbidity. There is an urgent need for an effective therapy that can restore skeletal growth and improve patients’ quality of life.

Ongoing research into achondroplasia has led to the discovery of potential therapies that might alleviate some of the symptoms and complications associated with the condition. Emerging therapies like Ascendis Pharma’s TransCon CNP (navepegritide) and QED Therapeutics (BridgeBio)/Novartis’ infigratinib (BBP-831/BGJ398) have the potential to quench the thirst for effective therapies. The achondroplasia market will change during the forecast period due to the expected approval of these emerging therapies, leading to the entry of new players in the treatment landscape.

TransCon CNP (navepegritide) is a prodrug of CNP administrated subcutaneously that regulates bone growth by maintaining CNP levels into growth plates. The delivery of TransCon CNP requires fewer doses and less quantity of CNP to elicit the therapeutic effects compared to the approved therapy VOXZOGO (vosoritide). Per DelveInsight’s analysts, the drug is anticipated to enter the US market by 2025.

Infigratinib (BBP-831/BGJ398) is an FGFR1-3 tyrosine kinase inhibitor that targets both the pathways, MAPK and STAT1, responsible for the clinical phenotype associated with achondroplasia. Further, its oral and painless administration spares children from the uncomfortable injection approach. The drug is anticipated to enter the US market by 2026 having a medium uptake.

Achondroplasia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Achondroplasia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Achondroplasia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Achondroplasia Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

The Report Covers the Achondroplasia Epidemiology, Segmented as –

Total Prevalent Cases of Achondroplasia [2019–2032]

Age-Specific Cases of Achondroplasia [2019–2032]

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Achondroplasia market or expected to be launched during the study period. The analysis covers the Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Achondroplasia Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/report-store/achondroplasia-market

Achondroplasia Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Achondroplasia. Currently, BioMarin Pharmaceutical is leading the therapeutics market with its Achondroplasia drug candidates in the most advanced stage of clinical development.

Leading Companies in the Achondroplasia Therapeutics Market Include:

Ascendis Pharma

BioMarin Pharmaceutical

Pfizer

PhaseBio Pharmaceuticals

ProLynx Inc

QED Therapeutics (BridgeBio)

Ribomic

Sanofi

And Many Others

Achondroplasia Emerging and Marketed Drugs Covered in the Report Include:

BMN-111: BioMarin Pharmaceutical

CNP-ELP: PhaseBio

Infigratinib: QED Therapeutics (BridgeBio)

PLX138: ProLynx Inc

Recifercept (TA 46): Pfizer

SAR442501: Sanofi

TransCon CNP: Ascendis Pharma

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/achondroplasia-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Achondroplasia Competitive Intelligence Analysis

4. Achondroplasia Market Overview at a Glance

5. Achondroplasia Disease Background and Overview

6. Achondroplasia Patient Journey

7. Achondroplasia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Achondroplasia Treatment Algorithm, Current Treatment, and Medical Practices

9. Achondroplasia Unmet Needs

10. Key Endpoints of Achondroplasia Treatment

11. Achondroplasia Marketed Products

12. Achondroplasia Emerging Drugs and Latest Therapeutic Advances

13. Achondroplasia Seven Major Market Analysis

14. Attribute Analysis

15. Achondroplasia Market Outlook (In US, EU5, and Japan)

16. Achondroplasia Access and Reimbursement Overview

17. KOL Views on the Achondroplasia Market

18. Achondroplasia Market Drivers

19. Achondroplasia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download a free sample report @ https://www.delveinsight.com/sample-request/achondroplasia-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Achondroplasia Market is Expected to Show a Significant Growth During the Forecast Period | Pfizer, Sanofi, ProLynx, PhaseBio, Ascendis, BioMarin

Adenoid Cystic Carcinoma Market to Grow at a Substantial Growth Rate During the Forecast Period | HLB, Ayala Pharma, Merck, Amgen, CureVac, Actuate Therapeutics

“Adenoid Cystic Carcinoma Market”

According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming years due to the anticipated introduction of new therapies, increased awareness of the disease, and advancements in research and development by leading biotech companies.

The emerging pipeline for the treatment of Adenoid Cystic Carcinoma is robust. Pharmaceutical companies like Merck, Ayala Pharmaceuticals, etc., are investigating many combination products in this disease area.

DelveInsight’s “Adenoid Cystic Carcinoma (ACC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adenoid Cystic Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Adenoid Cystic Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Adenoid Cystic Carcinoma Overview

Adenoid cystic carcinoma (ACC) is a rare type of adenocarcinoma that originates in glandular tissue. It most commonly develops in the salivary glands or other areas of the head and neck, but it can also appear in other body parts. ACC tumors are distinguished by a unique histological pattern of abnormal “nests” or cords of epithelial cells that surround or invade ducts or glandular structures within the affected organ. These structures often contain mucous-like material or abnormal fibrous membranes, which are visible under microscopic examination.

ACC is considered a low-grade malignancy with slow growth. While it is rarely invasive and generally does not affect nearby lymph nodes or perineural spaces, it tends to recur locally. Approximately half of the patients experience metastasis to distant sites, especially the lungs, leading to potentially life-threatening complications. Unlike many other carcinomas, most ACC patients survive for at least 5 years, although tumors often recur and progress after this period.

Adenoid Cystic Carcinoma Market Key Facts

According to Calderón Boyle et al. (2020), in the US, the Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75–79 years and in females and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.

According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively, with treatment failure in 46% cases while distant failures in 34%.

Several major pharma and biotech companies are working in the Adenoid Cystic Carcinoma Market, such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co, and others.

Adenoid Cystic Carcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Adenoid Cystic Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Adenoid Cystic Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Adenoid Cystic Carcinoma Epidemiology Assessment

The Report Covers the Adenoid Cystic Carcinoma Epidemiology, Segmented as –

Total Incidence Cases of ACC in the 7MM [2019–2032]

Gender-specific Incidence cases of ACC in the 7MM [2019–2032]

Grade-specific Incidence cases of ACC in the 7MM [2019-2032]

Treatable cases of ACC in the 7MM [2019-2032]

Adenoid Cystic Carcinoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Adenoid Cystic Carcinoma market or expected to be launched during the study period. The analysis covers the Adenoid Cystic Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Adenoid Cystic Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Adenoid Cystic Carcinoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Adenoid Cystic Carcinoma Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Adenoid Cystic Carcinoma. Ayala Pharmaceuticals is leading the therapeutics market with its Adenoid Cystic Carcinoma drug candidates in the most advanced stage of clinical development.

Leading Companies in the Adenoid Cystic Carcinoma Therapeutics Market Include:

Ayala Pharmaceuticals

CureVac

Elevar Therapeutics

Actuate Therapeutics

Merck & Co.

SHEPHERD Therapeutics

Actuate Therapeutics

Amgen

And Many Others

Adenoid Cystic Carcinoma Emerging and Marketed Drugs Covered in the Report Include:

Rivoceranib : HLB

Lenvatinib and Pembrolizumab: Merck

AL101: Ayala Pharmaceuticals

AMG 232 : Amgen

CV8102: CureVac AG

Elraglusib: Actuate Therapeutics

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Adenoid Cystic Carcinoma Competitive Intelligence Analysis

4. Adenoid Cystic Carcinoma Market Overview at a Glance

5. Adenoid Cystic Carcinoma Disease Background and Overview

6. Adenoid Cystic Carcinoma Patient Journey

7. Adenoid Cystic Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Adenoid Cystic Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Adenoid Cystic Carcinoma Unmet Needs

10. Key Endpoints of Adenoid Cystic Carcinoma Treatment

11. Adenoid Cystic Carcinoma Marketed Products

12. Adenoid Cystic Carcinoma Emerging Drugs and Latest Therapeutic Advances

13. Adenoid Cystic Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Adenoid Cystic Carcinoma Market Outlook (In US, EU5, and Japan)

16. Adenoid Cystic Carcinoma Access and Reimbursement Overview

17. KOL Views on the Adenoid Cystic Carcinoma Market

18. Adenoid Cystic Carcinoma Market Drivers

19. Adenoid Cystic Carcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Download a free sample report @ https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adenoid Cystic Carcinoma Market to Grow at a Substantial Growth Rate During the Forecast Period | HLB, Ayala Pharma, Merck, Amgen, CureVac, Actuate Therapeutics

Lipodystrophy Market to Show Substantial Growth During the Forecast Period | CombiGene, Galmed, Cell Praxis, Regeneron, Amryt Pharma, Zydus Cadila

“Lipodystrophy Market”

According to DelveInsight, the dynamics of the Lipodystrophy market are expected to shift in the coming years due to increased global healthcare spending and the anticipated introduction of new therapies.

As per DelveInsight, the Lipodystrophy market dynamics are anticipated to change in the coming years owing to the rise in healthcare spending worldwide and the expected launch of emerging therapies.Currently, some of the key companies, such as Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others, are involved in drug development for Lipodystrophy. The emerging therapies for the treatment of Lipodystrophy include Volanesorsen, REGN4461, Empagliflozin, and others. Approval of these therapies will provide new and different treatment options to the patients and will hence drive the market.

DelveInsight’s “Lipodystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lipodystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Lipodystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Lipodystrophy Overview

Lipodystrophy is characterized by either a complete or partial loss of adipose tissue (lipoatrophy), which may occur alongside abnormal accumulation of adipose tissue (lipohypertrophy) in other body areas. This condition leads to various metabolic complications, highlighting the role of adipose tissue as a crucial endocrine organ. The amount and distribution of adipose tissue significantly impact metabolic health.

Lipodystrophy can be either inherited or acquired, with inherited forms being extremely rare. In patients with lipodystrophy, levels of circulating hormones secreted by adipose tissue, such as leptin and adiponectin, are often significantly reduced.

Recent advancements in understanding the disease mechanisms have led to new diagnostic and therapeutic strategies for lipodystrophy. Ongoing research and development are expected to introduce innovative therapies that address current unmet needs and enhance treatment options for the condition.

Lipodystrophy Market Key Facts

In 2021, the US had the largest Lipodystrophy market size of ~USD 77 million among the 7MM countries.

Among the EU4 countries, France had the highest market size for Lipodystrophy in 2021, i.e., ~USD 26 million.

The lowest market size among EU4 countries was estimated in Italy, with ~USD 9 million in 2021.

The market size of Lipodystrophy in the UK was observed to be ~USD 8 million in 2021.

In 2021, the total incident cases of Lipodystrophy in the US were ~1,050 cases.

EU4 and the UK, in 2021, accounted for ~1,850 cases of Lipodystrophy, which are anticipated to increase by the year 2032.

Among the EU4 countries, the highest number of cases of Lipodystrophy was found in France, i.e., ~760 cases in the year 2021.

Lipodystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Lipodystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Lipodystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Lipodystrophy Epidemiology Assessment

The Report Covers the Lipodystrophy Epidemiology, Segmented as –

Total Cases of Lipodystrophy in the 7MM [2019–2032]

Subtype-specific Cases of Lipodystrophy in the 7MM [2019–2032]

Gender-specific Cases of Lipodystrophy in the 7MM [2019–2032]

Lipodystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lipodystrophy market or expected to be launched during the study period. The analysis covers the Lipodystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lipodystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Lipodystrophy Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/lipodystrophy-market

Lipodystrophy Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Lipodystrophy. Regeneron Pharmaceuticals is leading the therapeutics market with its Lipodystrophy drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Lipodystrophy Therapeutics Market Include:

Amryt Pharma

Boehringer Ingelheim

Carmot Therapeutics

Cell Praxis

CombiGene

Galmed Pharmaceuticals

Ionis Pharmaceuticals

Lipigon Pharmaceuticals

Regeneron Pharmaceuticals

Thera Technologies

Zydus Cadila

And Many Others

Lipodystrophy Emerging and Marketed Drugs Covered in the Report Include:

Aramchol: Galmed Pharmaceuticals

CT-SCUP: Cell Praxis

EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies

Empagliflozin: Boehringer Ingelheim

Gene therapy: CombiGene

Mibavademab: Regeneron Pharmaceuticals

MYALEPT (metreleptin): Amryt Pharma

REGN4461: Regeneron Pharmaceuticals

Saroglitazar Magnesium: Zydus Cadila

WAYLIVRA (volanesorsen): Ionis Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/lipodystrophy-market

Table of Content

1. Key Insights

2. Executive Summary

3. Lipodystrophy Competitive Intelligence Analysis

4. Lipodystrophy Market Overview at a Glance

5. Lipodystrophy Disease Background and Overview

6. Lipodystrophy Patient Journey

7. Lipodystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Lipodystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Lipodystrophy Unmet Needs

10. Key Endpoints of Lipodystrophy Treatment

11. Lipodystrophy Marketed Products

12. Lipodystrophy Emerging Drugs and Latest Therapeutic Advances

13. Lipodystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Lipodystrophy Market Outlook (In US, EU5, and Japan)

16. Lipodystrophy Access and Reimbursement Overview

17. KOL Views on the Lipodystrophy Market

18. Lipodystrophy Market Drivers

19. Lipodystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lipodystrophy Market to Show Substantial Growth During the Forecast Period | CombiGene, Galmed, Cell Praxis, Regeneron, Amryt Pharma, Zydus Cadila

Noëlle Fueter, Purpose Coach, Top Amazon Best-Seller Lists With New Book “The Animal Code”

In this book, Noëlle Fueter shares her inspirational journey of overcoming adversity and finding purpose through her profound connection with animals. Her new book hit best-seller lists on Amazon.com and ranked in the Kindle categories:

#1 Best Seller Animal and Comparative Psychology #1 Hot New Release Evolutionary Psychology #1 Hot New Release Animal and Comparative Psychology #4 Hot New Release Personal Transformation and Spirituality #5 Best Seller Evolutionary Psychology

Fueter: “I am thrilled and humbled to see ‘The Animal Code’ reach #1 on Amazon. This is more than just a book. This book is not only a story of strength and resilience, but it is also a resource for you to discover your truest self! This is the beginning of your enlightenment. Embark on your own journey of making your heart sing. With the support of twelve wild animals and their natural wisdom, The Animal Code will guide you to uncovering and fulfilling your soul’s purpose.”

There comes a point where we all come to a crossroads and don’t know which path to take next. But with The Animal Code: 12 Steps to a Life of Purpose, you will unlock the secret to knowing exactly what you need to do next – and the best part is: you will never have to do it alone.

Video Link: https://www.youtube.com/embed/WpDbunHAGSc

In this book, Noëlle Fueter shares her inspirational journey of overcoming adversity and finding purpose through her profound connection with animals. It is an adventurous memoir – a truly emotional roller-coaster that reveals one woman’s incredible transformation made possible by her connection to the animal kingdom. Her life’s mission is to help others on their journey of personal transformation, connecting them with their animal guides to discover and live in their heart’s truth.

At the end of each chapter, participate in interactive activities that will connect you with each of the 12 amazing animal guides. Learn how each one can appear in your life to guide you through hardship and empower your transformation so that you can start living the life you deserve.

The book can be purchased on Amazon at: https://www.amazon.com/dp/B0DBRXRCRT

About The Author:

Noëlle Fueter is a purpose coach with great knowledge on relationship dynamics, a spiritual guide, a Magdalena energy practitioner and passionate advocate for animals. She lives a life deeply connected to nature in the serene Swiss countryside with her beloved husband Tobi and their three former stray dogs, Roma, Pipa and Devi.

As a small business owner of Citydogs and founder of their charity for stray animals The Dog Rose, Noëlle has dedicated her life to empowering others. Through her work over the past 20 years, she has guided hundreds to reconnect with their inner selves by exploring the profound wisdom and strength found in the animal kingdom. Noelle believes that this Love inspires deep personal growth, meaningful relationships and purpose, helping individuals harness the transformative power of their connections with animals.

Learn More: https://noelle.love/

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Carbon & Graphite Felt Market Growth Analysis, Size, Opportunities, Leading Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2029

“Browse 318 market data Tables and 53 Figures spread through 241 Pages and in-depth TOC on “Carbon & Graphite Felt Market””

The Carbon & Graphite Felt Market is expanding due to rising demand in aerospace, automotive, and energy sectors. Top regional growth is seen in North America and Asia-Pacific, driven by industrial advancements and technological innovations.

The carbon & graphite felt market is projected to grow USD 551 million in 2024 and is projected to reach USD 871 million by 2029, at a CAGR of 9.6% from 2024 to 2029. During the forecasted years, demand for renewable energy, growing wind power capacity expansions, and demand for superior batteries from various end-use industries is expected to drive the demand for carbon & graphite felt market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=15496274

Based on type, the carbon & graphite felt market is segmented on the basis of its type carbon felt and graphite felt. In terms of value, carbon felt type segment accounted for the highest market share in the global market. The increasing adoption of use of carbon felt in electrodes, batteries, and filters is expected to drive the market in the upcoming years.

Based on application, the market for carbon & graphite felt has been segmented into furnace, batteries, filters, and others. The battery’s application of carbon & graphite felt accounted for the second-largest market share in terms of both, volume and value in 2023. Carbon & graphite felt are widely used as vanadium redox flow batteries (VRFBs). Carbon & graphite felts help to reduce the polarization are electrodes resulting in the improved performance of batteries.

Based on raw material, the market for carbon & graphite felt has been segmented into PAN, rayon, and pitch. In 2023, PAN raw material segment accounted for the largest market share, in terms of both value and volume. PAN-based carbon felts and graphite felts is also expected to grow with a highest CAGR during the forecasting period. High insulation, lower cost, easy processing, and high strength modulus is expected to increase the demand for PAN-based carbon & graphite felts across the globe.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=15496274

Based on product type, the market for carbon & graphite felt has been segmented into rigid felt, and soft felt. Soft felt product type segment is expected to witness the highest CAGR in upcoming years. Soft felt provides low heat capacity, and lower thermal conductivity. Soft carbon & graphite felt get widely used in furnaces with inert gas atmospheres and vacuum furnaces.

Based on Region, North America is expected to grow with second highest CAGR during the forecast period. It is the third largest market for carbon & graphite felt based on both, value and volume. The US is the largest market in the region. The carbon & graphite felt market in the North America is mainly driven by the ongoing and rapid developments into flow batteries and metal treatment sector. The region is also a home to wide number of players operating in the flow battery sector having applications in industrial, military, utilities, and commercial applications.

Major players operating in the carbon & graphite felt market include SGL Carbon (Germany), Toray Industries, Inc. (Japan), Kureha Corporation (Japan), Nippon Carbon Co., Ltd. (Japan), Beijing Great Wall Co., Ltd. (China), Mersen (France), Chemshine Carbon Co., Ltd. (China), CM Carbon Co., Ltd. (China), Gansu Haoshi Carbon Fiber Co., Ltd. (China), and CFC Carbon Co., Ltd. (China). Many of these companies have reliable manufacturing facilities as well as wide and strong distribution networks across the world, such as Asia Pacific, North America, and Europe. The manufacturers have well-established portfolio of wide range of products and services, a robust global market presence, and strong business and growth strategies.

Inquire Now: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=15496274

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/carbon-graphite-felt-market-15496274.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Carbon & Graphite Felt Market Growth Analysis, Size, Opportunities, Leading Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2029

Epstein Barr Virus Market is Expected to Show a Remarkable Growth During the Forecast Period | Viracta, Atara Biotherapeutics, AlloVir

“Epstein Barr Virus (EBV) Market”

In 2021, the Epstein-Barr Virus market across the seven major markets was valued at approximately USD 1.5 billion. According to DelveInsight, this market is expected to experience significant growth in the coming years, driven by increased research and development efforts focused on the Epstein-Barr Virus and the anticipated introduction of new therapies, including Brentuximab Vedotin (Seagen) and other emerging treatments.

Various companies are working to develop therapies for the treatment of EBV+Cancers and PTLD. Key players such as Atara Biotherapeutics, Tessa Therapeutics, AlloVir are some of the major players that are going to boost the market dynamics in the coming years. The availability of these therapies may change the prescription patterns and the treatment scenario.

DelveInsight’s “Epstein Barr Virus (EBV) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epstein Barr Virus market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Epstein Barr Virus market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Epstein Barr Virus Overview

The Epstein–Barr virus (EBV), or human herpesvirus 4, is a widespread member of the Herpesviridae family. It is a common pathogen that remains in people globally throughout their lives. EBV is primarily responsible for infectious mononucleosis (IM) and is linked to several cancers, such as nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and post-transplant lymphomas.

Primary EBV infection often occurs in childhood and typically causes mild illness, frequently transmitted through body fluids like saliva, and becomes a latent infection in B-cells. By age 2–3, 20–80% of individuals are asymptomatic carriers. When adolescents and young adults who have never been infected with EBV are exposed, around 30–70% may develop infectious mononucleosis or other EBV-related conditions.

EBV exists in two main types: Type I and Type II, also referred to as Types A and B. These types are differentiated based on variations in the EBNA-2 gene. EBV strains can be further classified within these two types.

Epstein Barr Virus (EBV) Market Key Facts

The total number of Epstein–Barr Virus IM cases in the 7MM countries was more than 1,120,000 in 2021.
As per the estimates, the United States had the highest number of incident cases of Epstein–Barr Virus in 2021.
Among EU4 and the UK, Germany had the highest number of Epstein–Barr Virus cases, with more than 146,000 cases, followed by France in 2021.
Spain had the lowest number of Epstein–Barr Virus cases, with close to 79,000 cases in 202, among the Among EU4 and the UK.
EBV infection affects as many as 95% of American adults by age 35–40. Childhood EBV infection is indistinguishable from other transient childhood infections. Approximately 35-50% of adolescents and young adults who contract EBV infection have mononucleosis.

Epstein Barr Virus (EBV) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Epstein Barr Virus market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Epstein Barr Virus market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Epstein Barr Virus (EBV) Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

The Report Covers the Epstein Barr Virus Epidemiology, Segmented as –

Total Diagnosed cases of EBV Infectious Mononucleosis [2020–2034]
Total Incident cases of EBV+ Cancers [2020–2034]
Total Incident cases of EBV+ PTLD [2020–2034]
Total Incident cases of EBV-associated tumors in the 7MM [2020–2034]

Epstein Barr Virus (EBV) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Epstein Barr Virus market or expected to be launched during the study period. The analysis covers the Epstein Barr Virus market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epstein Barr Virus pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Epstein Barr Virus Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/epstein-barr-virus-ebv-market

Leading Companies in the Epstein Barr virus (EBV) Therapeutics Market Include:

Viracta Therapeutics
Atara Biotherapeutics
AlloVir
RAPT Therapeutics
Tessa Therapeutics

Epstein–Barr Virus (EBV) Emerging and Marketed Drugs Covered in the Report Include:

FLX475: RAPT Therapeutics
Nanatinostat: Viracta Therapeutics
Posoleucel (ALVR105): Allovir
Tabelecleucel: Atara Biotherapeutics
TT10: Tessa Therapeutics

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/epstein-barr-virus-ebv-market

Table of Contents

1. Key Insights

2. Executive Summary

3. Epstein Barr Virus Competitive Intelligence Analysis

4. Epstein Barr Virus Market Overview at a Glance

5. Epstein Barr Virus Disease Background and Overview

6. Epstein Barr Virus Patient Journey

7. Epstein Barr Virus Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Epstein Barr Virus Treatment Algorithm, Current Treatment, and Medical Practices

9. Epstein Barr Virus Unmet Needs

10. Key Endpoints of Epstein Barr Virus Treatment

11. Epstein Barr Virus Marketed Products

12. Epstein Barr Virus Emerging Drugs and Latest Therapeutic Advances

13. Epstein Barr Virus Seven Major Market Analysis

14. Attribute Analysis

15. Epstein Barr Virus Market Outlook (In US, EU5, and Japan)

16. Epstein Barr Virus Access and Reimbursement Overview

17. KOL Views on the Epstein Barr Virus Market

18. Epstein Barr Virus Market Drivers

19. Epstein Barr Virus Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epstein Barr Virus Market is Expected to Show a Remarkable Growth During the Forecast Period | Viracta, Atara Biotherapeutics, AlloVir

Opticargo Launches Comprehensive and Customizable Logistics Management System with Integrated Store App and Fleet Management Integration

Opticargo is a cutting-edge logistics and supply chain operating system designed to streamline and optimize various aspects of logistics operations, from fleet management to order processing. Our modular platform adapts to the unique operational needs of businesses across industries, including e-commerce, retail, courier services, and more. Learn more at opticargo.co.

Opticargo announces the launch of its new, fully customizable logistics management system, featuring a comprehensive Store App with Payment Gateway integration and advanced Fleet Management capabilities. This new platform is designed to empower businesses to streamline their logistics operations with key features like real-time Track & Trace, Route Optimization, and API Integration, ensuring complete visibility and control from order creation to final delivery.

Opticargo, a leader in logistics and supply chain management solutions, is proud to introduce its latest innovation – a modular, fully customizable logistics management system designed to adapt to the unique needs of businesses across various sectors. The newly launched platform is equipped with advanced features that optimize every stage of logistics operations, from fleet management to final delivery.

The highlight of this release is the Opticargo Store App, a comprehensive solution tailored for both e-commerce businesses and logistics operations. This versatile app empowers users to manage storefronts, product listings, inventory, and order processing seamlessly. With integrated payment gateway support, businesses can process transactions efficiently, ensuring a smooth workflow from order placement to delivery.

Key Features of the Opticargo Store App:

Fleet Management: Effortlessly optimize and manage your vehicle fleet, ensuring maximum efficiency.
Order Management: Seamlessly handle orders from creation to delivery, maintaining complete control over the process.
Track & Trace: Gain real-time visibility into your shipments, enhancing transparency and customer satisfaction.
Route Optimization: Improve routing efficiency, saving both time and costs, with our advanced algorithms.
Order Configuration: Tailor your order forms and workflows to match your specific business needs.
API Integration: Connect with other systems and tools for a unified operation, leveraging our robust API.
Fuel Reporting: Keep accurate track of fuel usage and costs, helping to manage expenses effectively.
Issue Management: Quickly address and resolve any issues with our integrated management tools.

Custom Shipment Workflow: Design and implement workflows that suit your logistics operations, from start to finish.

Additionally, the platform integrates with our Logistics Management System, a powerful tool that supports customizable driver management, including QR code scanning, digital signatures, and advanced routing features. Drivers can efficiently manage their shipments, update order activities in real-time, and even handle their finances with wallet management capabilities.

“Opticargo is designed to be the backbone of logistics operations, providing businesses with the tools they need to drive efficiency, reduce costs, and enhance customer satisfaction,” said Adam, Founder at Opticargo. “Our platform’s flexibility and customization options make it suitable for a wide range of industries, ensuring that our clients can meet their unique operational needs.”

Manager Dashboard: The Manager Dashboard offers a centralized hub where business owners and managers can monitor all aspects of their operations, from fleet status to order fulfillment, in real-time. This feature ensures that decision-makers have the information they need at their fingertips, allowing for quick adjustments and improvements as needed.

Marketplace Network & 3rd Party Integration: Opticargo’s Marketplace Network allows businesses to connect with a wide range of service providers and suppliers, expanding their operational capabilities. Our 3rd Party Integration support ensures that the platform can seamlessly work with other tools and systems, providing a truly unified logistics solution.

For more information about Opticargo and to schedule a demo, visit opticargo.co.

Media Contact
Company Name: Opticargo
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.opticargo.co/

Grammy-Nominated Mark Carman Unveils Heartfelt, Message-Heavy Album, “Pieces Of Me”

Singer-songwriter Mark Carman invites listeners on a deeply personal journey with his new album, “Pieces of Me”. A poignant exploration of fatherhood, love, and the passage of time, the eleven-track collection is a testament to Carman’s profound songwriting and musical artistry.

LISTEN

PRIVATE STREAM

DOWNLOAD PRESS IMAGE

Rooted in folk, Americana, and blues, “Pieces of Me” is a sonic tapestry woven with raw emotion and heartfelt lyricism. Each song is a chapter in the story of Carman’s life, a tribute to his children, and a celebration of shared experiences. From the nostalgic echoes of “Yesterday When I Was Young” to the unwavering devotion expressed in “That’s My Job,” the album is a profound reflection on the enduring bonds of family.

More than just a collection of songs, “Pieces of Me” is a legacy, a love letter, and an invitation to connect with the universal experiences of life. Carman’s signature blend of soulful vocals and masterful musicianship creates an album that is both intimately personal and profoundly resonant.

As listeners embark on this musical journey, they are invited to share the beauty, challenges, and joys shaping our lives. “Pieces of Me” is a reminder of the enduring power of love, the importance of cherishing moments, and the connections that bind us together.

ABOUT MARK CARMAN

Mark Carman is a Grammy-nominated producer, songwriter, musician, and singer, known for his deep passion for music and his heartfelt connection to family and faith. With a rich career spanning several decades, Mark’s artistry has touched countless lives, blending timeless melodies with personal narratives and spiritual insights.

Musical Journey

Mark Carman is celebrated for his role as the musical arranger and co-producer of the Grammy-nominated album “Forever Changed” by country music artist T. Graham Brown. This acclaimed album features guest performances by renowned artists such as Leon Russell, Vince Gill, The Oak Ridge Boys, and Jason Crabb. The recording musicians represented an all-star lineup, including notable names like David Hungate (bass guitar), Brent Mason (electric guitar), Steve Cropper (electric guitar), and Jim Horn (saxophone). ‘Read More…‘

FOLLOW MARK CARMAN – FACEBOOK

Contact: MCM World Media at 757-392-5000

Media Contact
Company Name: MCM World Media
Contact Person: Andrew Lewyn
Email: Send Email
Phone: 757-392-5000
Country: United States
Website: https://markcarmanmusic.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Grammy-Nominated Mark Carman Unveils Heartfelt, Message-Heavy Album, \”Pieces Of Me\”

AVENDOR Amplifies Presence in the Booming Pro AV Market as an Authorized Dealer for Over 150 Leading Brands, Including Barco

The Professional Audio-Visual Systems Market is poised for significant growth, with AVENDOR at the forefront, offering cutting-edge solutions like LCD and LED Video Walls, Large Venue Projectors, and more.

NEW YORK – Aug 15, 2024 – AVENDOR, a leading provider of professional audio-visual (Pro AV) solutions, is proud to announce its strategic positioning within the rapidly expanding Pro AV market. As an authorized dealer for over 150 top-tier brands, including Barco, Samsung, Planar, and Christie, AVENDOR continues to elevate the standards of quality and service in both residential and commercial AV spaces.

The Pro AV market is on a trajectory of robust growth, with the global market size estimated at USD 282.06 billion in 2024, projected to reach USD 354.06 billion by 2029. This growth is driven by advancements in audio and display technologies, the adoption of cloud solutions, and the increasing integration of Internet of Things (IoT) and Artificial Intelligence (AI) in smart buildings. AVENDOR is uniquely positioned to capitalize on these trends, offering a comprehensive range of products including LCD Video Walls, LED Video Walls, Large Format Displays, Outdoor Signage, Large Venue Projectors, PTZ Cameras, and Touch Displays. These innovative, energy-efficient, and cost-effective AV solutions are tailored to meet the diverse needs of its clientele.

“At AVENDOR, our mission is to transform spaces through cutting-edge Pro AV technology. Our partnership with leading brands like Barco enables us to deliver high-performance solutions that not only meet but exceed our clients’ expectations,” said Agil Huseynov, CEO and founder of AVENDOR. “With the Pro AV market experiencing unprecedented growth, we are committed to providing our customers with the best products and services, backed by our exceptional customer support.”

AVENDOR’s comprehensive service offering includes pre-sales consultancy, full AV system design, and expert installation support. By maintaining close relationships with clients and offering customized solutions, AVENDOR ensures that every project is executed with precision, delivering long-lasting performance and maximum return on investment.

About AVENDOR

AVENDOR is a premier provider of professional audio-visual solutions, specializing in innovative, energy-efficient, and cost-effective AV systems for residential and commercial spaces. With a deep commitment to customer satisfaction, AVENDOR offers a wide range of products sourced from over 150 leading brands, including Barco, Samsung, Planar, and Christie. Our product lines include LCD Video Walls, LED Video Walls, Large Format Displays, Outdoor Signage, Large Venue Projectors, PTZ Cameras, and Touch Displays. The company provides end-to-end services, from consultancy and design to installation and support, ensuring a seamless experience for its clients. AVENDOR operates from 11 strategically located warehouses across the United States, guaranteeing fast and reliable product delivery.

For more information, visit https://www.avendor.com/

Media Contact
Company Name: AVENDOR
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.avendor.com/

Tech Entrepreneur Olutosin Alabi Is Revolutionizing Diabetic Care With AI-Powered Wearables

In the bustling world of health tech startups, one name is quickly rising to the forefront: Olutosin Alabi. The Nigerian-born entrepreneur and current MBA candidate at Syracuse University’s Whitman School of Management is making waves with her innovative approach to managing one of diabetes’ most pervasive complications: foot ulcers.

Alabi’s company, DiabeTech, is poised to disrupt the $50 billion global diabetes care market with its AI-powered wearable technology. “We’re not just creating a product,” Alabi explains, “we’re igniting a movement towards patient empowerment in diabetes management.”

DiabeTech’s platform integrates electronic tattoo sensors, AI analytics, and a user-friendly mobile app to provide real-time monitoring and personalized treatment recommendations for diabetic foot ulcer patients. This novel approach could significantly reduce the $9.1 billion spent annually on diabetic foot ulcer treatment in the U.S. alone. Alabi said, “I see immense potential in this innovation. DiabeTech addresses a critical gap in diabetes care. By providing continuous monitoring and early intervention, we could potentially prevent thousands of amputations each year.”

Alabi’s journey from software engineer to health tech innovator is as impressive as her product. With a BSc in Computing from the University of Greenwich and an MSc in Information Technology from The Open University, Alabi brings a unique blend of technical expertise and business acumen to the healthcare sector. Her entrepreneurial prowess hasn’t gone unnoticed. Alabi’s track record of success dates back to 2012 when she received the Youth Enterprise with Innovation in Nigeria award, in conjunction with the World Bank. This early recognition set the stage for a series of accolades, including the Bank of Industry Nigeria YES Grant in 2016 and the Tony Elumelu Foundation Business Award in 2018.Most recently, in 2024, Alabi has been on a winning streak. She secured business grants in the Afroprenure Competition, followed by a win in the Raymond von Dran iPrize Competition. The crowning achievement came with victory in the Whitman School of Management Dean’s Innovation Competition, among others.

Sarah Johnson, a partner at eHealthTech Ventures, sees Alabi as a rising star in the industry. “Olutosin represents the best of what young entrepreneurs can achieve when they combine technical expertise with a deep understanding of real-world problems,” Johnson states. “Her consistent recognition across various competitions speaks volumes about her potential to disrupt the healthcare industry.”

With the global digital health market projected to reach $639.4 billion by 2026, according to MarketsandMarkets research, Alabi’s timing couldn’t be better. Olutosin Alabi is not just positioned to transform diabetic care – she’s on track to become a formidable player in the health tech industry, backed by a strong history of entrepreneurial success and recognition.

Media Contact
Company Name: DiabeTech
Contact Person: Olutosin Alabi
Email: Send Email
Country: United States
Website: diabetech.io